Stockscreener 앱 받기
11.81
2.25%
0.26
시간 외 거래:
11.50
-0.31
-2.62%
전일 마감가:
$11.55
열려 있는:
$11.85
하루 거래량:
920.22K
Relative Volume:
0.81
시가총액:
$930.61M
수익:
$175.11M
순이익/손실:
$-221.25M
주가수익비율:
-3.8702
EPS:
-3.0515
순현금흐름:
$-167.00M
1주 성능:
+6.01%
1개월 성능:
+10.68%
6개월 성능:
+6.88%
1년 성능:
+177.88%
1일 변동 폭
$11.68
$12.17
1주일 범위
$10.80
$12.17
52주 변동 폭
$2.21
$18.31
Phathom Pharmaceuticals Inc Stock (PHAT) Company Profile
명칭
Phathom Pharmaceuticals Inc
전화
(877) 742-8466
주소
100 CAMPUS DRIVE,, FLORHAM PARK, NJ
Compare PHAT vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
PHAT
Phathom Pharmaceuticals Inc
|
11.81 | 910.13M | 175.11M | -221.25M | -167.00M | -3.0515 |
VRTX
Vertex Pharmaceuticals Inc
|
443.92 | 109.85B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
775.53 | 80.38B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
785.07 | 47.60B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
327.25 | 42.63B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
312.19 | 33.72B | 5.36B | 287.73M | 924.18M | 2.5229 |
Phathom Pharmaceuticals Inc Stock (PHAT) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-03-27 | 업그레이드 | Barclays | Equal Weight → Overweight |
| 2025-12-12 | 개시 | Raymond James | Strong Buy |
| 2025-12-09 | 개시 | Barclays | Equal Weight |
| 2025-02-14 | 개시 | Cantor Fitzgerald | Overweight |
| 2024-05-03 | 개시 | Stifel | Buy |
| 2024-01-05 | 재확인 | Needham | Buy |
| 2023-08-09 | 개시 | H.C. Wainwright | Buy |
| 2023-05-11 | 업그레이드 | Evercore ISI | In-line → Outperform |
| 2023-03-13 | 개시 | Craig Hallum | Buy |
| 2022-10-21 | 개시 | Jefferies | Buy |
| 2022-05-06 | 다운그레이드 | Evercore ISI | Outperform → In-line |
| 2021-05-12 | 업그레이드 | Goldman | Sell → Neutral |
| 2021-02-17 | 개시 | BMO Capital Markets | Outperform |
| 2021-02-02 | 개시 | Guggenheim | Buy |
| 2020-06-26 | 다운그레이드 | Goldman | Neutral → Sell |
| 2019-11-20 | 개시 | Evercore ISI | Outperform |
| 2019-11-19 | 개시 | Goldman | Neutral |
| 2019-11-19 | 개시 | Jefferies | Buy |
| 2019-11-19 | 개시 | Needham | Buy |
모두보기
Phathom Pharmaceuticals Inc 주식(PHAT)의 최신 뉴스
Aug Highlights: Is Phathom Pharmaceuticals Inc a cyclical or defensive stock2026 Big Picture & AI Optimized Trading Strategy Guides - baoquankhu1.vn
Phathom Pharmaceuticals (NASDAQ: PHAT) sets 2026 virtual meeting, director elections and say-on-pay vote - Stock Titan
Quarterly Recap: How correlated is Phathom Pharmaceuticals Inc to the S P5002026 Sector Moves & Fast Gaining Stock Reports - baoquankhu1.vn
Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences - ChartMill
Portfolio Recap: Is Phathom Pharmaceuticals Inc a cyclical or defensive stockQuarterly Profit Report & Weekly Stock Breakout Alerts - baoquankhu1.vn
PHAT Technical Analysis & Stock Price Forecast - Intellectia AI
Hennion & Walsh Asset Management Inc. Buys New Shares in Phathom Pharmaceuticals, Inc. $PHAT - MarketBeat
PHAT SEC FilingsPhathom Pharmaceuticals, Inc. 10-K, 10-Q, 8-K Forms - Stock Titan
Understanding the Setup: (PHAT) and Scalable Risk - Stock Traders Daily
Portfolio Recap: What are the risks of holding Phathom Pharmaceuticals IncWeekly Trend Report & Weekly High Return Forecasts - baoquankhu1.vn
Phathom Pharmaceuticals Inc (PHAT) Stock News & Articles - 247wallst.com
Phathom upgraded at Barclays following pullback, Voquezna optimism - MSN
Barclays upgrades Phathom Pharmaceuticals (PHAT) - MSN
Phathom upgraded at Barclays following pullback, Voquezna optimism ) - Seeking Alpha
Phathom Pharmaceuticals Upgraded by Barclays to Overweight With $18 Target - AOL.com
Phathom Pharmaceuticals (NASDAQ:PHAT) Shares Gap Up After Analyst Upgrade - MarketBeat
This Argan Analyst Turns Bullish; Here Are Top 3 Upgrades For Friday - Benzinga
Phathom Pharmaceuticals (NASDAQ:PHAT) Upgraded at Barclays - MarketBeat
Barclays Upgrades Phathom Pharmaceuticals to Overweight From Equal Weight, Adjusts PT to $18 From $16 - MarketScreener
Barclays upgrades Phathom Pharmaceuticals stock rating on revenue outlook - investing.com
Barclays upgrades Phathom Pharmaceuticals stock rating on revenue outlook By Investing.com - Investing.com Canada
Weekly Recap: Does Phathom Pharmaceuticals Inc offer margin of safetyTrade Performance Summary & Fast Momentum Entry Tips - baoquankhu1.vn
Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) Given Average Recommendation of "Moderate Buy" by Brokerages - MarketBeat
ETF Watch: Whats Phathom Pharmaceuticals Incs historical return2026 Market WrapUp & Weekly High Return Forecasts - baoquankhu1.vn
Analyst Calls: Does Phathom Pharmaceuticals Inc offer margin of safetyMarket Activity Recap & Safe Entry Momentum Tips - baoquankhu1.vn
Millennium (PHAT) group discloses 4.18M shares (5.3%) in Phathom (PHAT) - Stock Titan
Phathom Pharmaceuticals (PHAT) director gifts 80,000 shares to trust - Stock Titan
Mineralys Stock Rises as FDA Accepts NDA for Hypertension Drug - The Globe and Mail
Phathom Pharmaceuticals (PHAT) Stock Analysis Report | Ratings, Financials & Performance - Benzinga Japan
Precision Trading with Phathom Pharmaceuticals Inc. (PHAT) Risk Zones - Stock Traders Daily
Certain Performance Stock Units of Phathom Pharmaceuticals, Inc. are subject to a Lock-Up Agreement Ending on 9-MAR-2026. - marketscreener.com
Certain Common Stock of Phathom Pharmaceuticals, Inc. are subject to a Lock-Up Agreement Ending on 9-MAR-2026. - marketscreener.com
Phathom projects $1B GI market opportunity as sales realignment drives 25% revenue growth - MSN
GW&K Investment Management LLC Has $13.47 Million Stock Position in Phathom Pharmaceuticals, Inc. $PHAT - MarketBeat
Tech Rally: Does Phathom Pharmaceuticals Inc have strong fundamentalsQuarterly Trade Review & AI Forecast Swing Trade Picks - baoquankhu1.vn
PHAT Should I Buy - Intellectia AI
Propel Bio Management LLC Sells 370,000 Shares of Phathom Pharmaceuticals, Inc. $PHAT - MarketBeat
Phathom Pharmaceuticals Charts Profitable Path After Ramp-Up - TipRanks
PHAT Technical Analysis & ETF Price Forecast - Intellectia AI
Phathom Pharmaceuticals Hits Day Low of $12.32 Amid Price Pressure - Markets Mojo
Phathom (PHAT) accounting chief gets RSUs, surrenders shares for tax - Stock Titan
PHAT Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Phathom (PHAT) Q4 2025 Earnings Call Transcript - AOL.com
Phathom Pharmaceuticals (NASDAQ:PHAT) Stock Price Down 6.5%Should You Sell? - MarketBeat
Helicobacter pylori Infection Market: Accelerating Growth and Pipeline Impact by 2034 – DelveInsight | RedHill Biopharma, Phathom Pharma, Takeda Pharma, Otsuka Pharma, Juvisé Pharma, AbbVie, TenNor - Barchart.com
Guggenheim Raises PT on Phathom Pharmaceuticals (PHAT) to $25 From $20, Here’s Why - Insider Monkey
Guggenheim Raises PT on Phathom Pharmaceuticals (PHAT) to $25 From $20, Here's Why - Bitget
Phathom Pharmaceuticals (PHAT) Is Up 10.0% After Guiding to 2026 Operating Profitability and Raising Capital - simplywall.st
Phathom Pharmaceuticals: Early VOQUEZNA Traction, Strengthened Balance Sheet, and Clear Path to Profitability Support Buy Rating - TipRanks
Phathom Pharmaceuticals (NASDAQ:PHAT) Posts Earnings Results, Beats Expectations By $0.01 EPS - MarketBeat
Why Phathom Pharmaceuticals (PHAT) Is Up 13.2% After Guiding To 2026 Operating Profitability And Narrower Losses - Yahoo Finance
Phathom Pharmaceuticals Inc (PHAT) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Phathom Pharmaceuticals Inc 주식 (PHAT) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Parikh Asit | Director |
Dec 19 '25 |
Option Exercise |
10.30 |
8,750 |
90,125 |
122,250 |
| Basta Steven L | President and CEO |
Nov 28 '25 |
Option Exercise |
0.00 |
90,000 |
0 |
131,625 |
| Breedlove Robert Charles | Principal Accounting Officer |
Nov 03 '25 |
Sale |
13.51 |
524 |
7,079 |
47,407 |
| Basta Steven L | President and CEO |
Sep 25 '25 |
Option Exercise |
0.00 |
90,000 |
0 |
90,000 |
| Breedlove Robert Charles | Principal Accounting Officer |
Sep 05 '25 |
Sale |
12.09 |
461 |
5,573 |
47,931 |
| Breedlove Robert Charles | Principal Accounting Officer |
Jul 16 '25 |
Sale |
8.36 |
1,692 |
14,152 |
48,392 |
| Topper James N | Director |
May 21 '25 |
Buy |
3.86 |
3,780 |
14,609 |
59,403 |
| Topper James N | Director |
May 14 '25 |
Buy |
3.32 |
6,300 |
20,919 |
55,623 |
| Topper James N | Director |
May 13 '25 |
Buy |
3.16 |
1,120 |
3,543 |
49,323 |
| Topper James N | Director |
May 09 '25 |
Buy |
3.22 |
35,602 |
114,616 |
35,602 |
1.51%
1.75%
자본화:
|
볼륨(24시간):